Evidence map›Paper›PMID 26225222›Full record

ArticleCPT: pharmacometrics & systems pharmacology2015

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.

C Laouénan, J Guedj, G Peytavin, Th Tram Nguyen, M Lapalus, F Khelifa-Mouri, N Boyer, F Zoulim, L Serfaty, J-P Bronowicki and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. HCV Kinetic Models and Their Implications in Drug Development.CPT: pharmacometrics & systems pharmacology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

C LaouénanINSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France ; AP-HP, Hôpital Bichat, Departement of Biostatistic Paris, France.
J GuedjINSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France.
G PeytavinINSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France ; AP-HP, Hôpital Bichat, Department of Pharmaco-Toxicology Paris, France.
Th Tram NguyenINSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France.
M LapalusINSERM, CRI Paris Montmartre, UMR 1149, Univ Paris Diderot Clichy, France.
F Khelifa-MouriAP-HP, Hôpital Beaujon, Hepatology, Physiopathology and Treatment of Viral Hepatitis Clichy, France.
N BoyerAP-HP, Hôpital Beaujon, Hepatology, Physiopathology and Treatment of Viral Hepatitis Clichy, France.
F ZoulimINSERM, UMR 1052, Univ Lyon Lyon, France ; Hospices Civils de Lyon, Department of Hepatology Lyon, France.
L SerfatyAP-HP, Hôpital Saint-Antoine, Department of Hepatology Paris, France.
J-P BronowickiINSERM, UMR 954, Univ Lorraine Vandoeuvre-les-Nancy, France ; Centre Hospitalier Universitaire de Nancy, Department of Hepatology Vandoeuvre-les-Nancy, France.
M Martinot-PeignouxINSERM, CRI Paris Montmartre, UMR 1149, Univ Paris Diderot Clichy, France.
O LadaINSERM, CRI Paris Montmartre, UMR 1149, Univ Paris Diderot Clichy, France.
T AsselahINSERM, CRI Paris Montmartre, UMR 1149, Univ Paris Diderot Clichy, France ; AP-HP, Hôpital Beaujon, Hepatology, Physiopathology and Treatment of Viral Hepatitis Clichy, France.
C DorivalINSERM, UMR 1136, Univ Pierre et Marie Curie Paris, France.
C HézodeINSERM, UMR 955, Univ Paris-Est Créteil, France ; AP-HP, Hôpital Henri Mondor, Department of Hepatology Créteil, France.
F CarratINSERM, UMR 1136, Univ Pierre et Marie Curie Paris, France ; AP-HP, Hôpital Saint-Antoine, Department of Public Health Paris, France.
F NicotCHU Toulouse, IFB Purpan, Virology Laboratory Toulouse, France.
P MarcellinINSERM, CRI Paris Montmartre, UMR 1149, Univ Paris Diderot Clichy, France ; AP-HP, Hôpital Beaujon, Hepatology, Physiopathology and Treatment of Viral Hepatitis Clichy, France.
F MentréINSERM, IAME, UMR 1137, Univ Paris Diderot Sorbonne Paris Cité, Paris, France ; AP-HP, Hôpital Bichat, Departement of Biostatistic Paris, France.
Inserm · FRHôpital Beaujon · FRSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hézode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.1,2 Using frequent measurements of serum drug concentrations, hemoglobin, and platelet concentrations obtained in 15 patients of this cohort, we show how an on-treatment model-based approach could be used to individualize dose regimen and avoid the occurrence of RBV-induced anemia and Peg-IFN-induced thrombocytopenia.

Identifiers

PMID26225222
PMCPMC4369757
OpenAlexW1542341307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.